NYSEAMERICAN:ATNM - Actinium Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Actinium Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.25 0.00 (0.00 %) (As of 02/21/2020 07:43 AM ET) Add Compare Today's Range$0.24Now: $0.25▼$0.2650-Day Range N/A52-Week Range$0.19Now: $0.25▼$0.71Volume1.28 million shsAverage Volume2.91 million shsMarket Capitalization$41.24 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsAdvanced ChartEarningsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Actinium Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant. Read More… Industry, Sector and Symbol Stock Exchange NYSEAMERICAN Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNYSEAMERICAN:ATNM Previous SymbolAMEX:ATNM CUSIPN/A CIKN/A Webhttp://www.actiniumpharmaceuticals.com/ Phone+1-646-6773875Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees30 Outstanding Shares164,171,000Market Cap$41.24 million Next Earnings Date3/17/2020 (Estimated) OptionableOptionable Receive ATNM News and Ratings via Email Sign-up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter. AMEX:ATNM Rates by TradingView Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Frequently Asked Questions What is Actinium Pharmaceuticals' stock symbol? Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ATNM." How were Actinium Pharmaceuticals' earnings last quarter? Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) posted its quarterly earnings results on Monday, March, 16th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.02. View Actinium Pharmaceuticals' Earnings History. When is Actinium Pharmaceuticals' next earnings date? Actinium Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 17th 2020. View Earnings Estimates for Actinium Pharmaceuticals. What price target have analysts set for ATNM? 3 brokerages have issued 12-month price objectives for Actinium Pharmaceuticals' stock. Their forecasts range from $1.50 to $5.00. On average, they anticipate Actinium Pharmaceuticals' stock price to reach $3.25 in the next twelve months. This suggests a possible upside of 1,193.8% from the stock's current price. View Analyst Price Targets for Actinium Pharmaceuticals. What is the consensus analysts' recommendation for Actinium Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Actinium Pharmaceuticals. What are Wall Street analysts saying about Actinium Pharmaceuticals stock? Here are some recent quotes from research analysts about Actinium Pharmaceuticals stock: 1. According to Zacks Investment Research, "Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company's principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. " (1/20/2020) 2. Maxim Group analysts commented, "Actinium reported 4Q18 and FY18 with a net loss of ($6.4M) and ($23.7M), respectively. The company ended the year with $13.6M in cash on the balance sheet (not including $2.5M warrant exercises). The company also has a $30M ATM in place. Combined, the company should have sufficient runway to get the P3 data for Iomab in 1H20." (3/20/2019) Has Actinium Pharmaceuticals been receiving favorable news coverage? News articles about ATNM stock have trended somewhat positive on Friday, according to InfoTrie Sentiment Analysis. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Actinium Pharmaceuticals earned a coverage optimism score of 1.3 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the next few days. View News Stories for Actinium Pharmaceuticals. Are investors shorting Actinium Pharmaceuticals? Actinium Pharmaceuticals saw a decrease in short interest in the month of January. As of January 31st, there was short interest totalling 2,310,000 shares, a decrease of 34.0% from the January 15th total of 3,500,000 shares. Based on an average daily trading volume, of 3,350,000 shares, the short-interest ratio is currently 0.7 days. Currently, 1.5% of the company's shares are sold short. View Actinium Pharmaceuticals' Current Options Chain. Who are some of Actinium Pharmaceuticals' key competitors? Some companies that are related to Actinium Pharmaceuticals include Senesco Technologies (ELOX), CorMedix (CRMD), CorMedix (CRMD), Burcon NutraScience (BU), Ampliphi Biosciences (APHB), Immutep (IMM), 22nd Century Group (XXII), MediGene (MDG1), OncoCyte (OCX), OncoCyte (OCX), Novoheart (NVH), Verseon (VSN), Imugene (IMU), Arix Bioscience (ARIX) and Faron Pharmaceuticals Oy (FARN). What other stocks do shareholders of Actinium Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Actinium Pharmaceuticals investors own include OHR Pharmaceutical (OHRP), Fitbit (FIT), Global Ship Lease (GSL), Opko Health (OPK), TransEnterix (TRXC), Sorrento Therapeutics (SRNE), Tandem Diabetes Care (TNDM), Cancer Genetics (CGIX), Align Technology (ALGN) and Inovio Pharmaceuticals (INO). Who are Actinium Pharmaceuticals' key executives? Actinium Pharmaceuticals' management team includes the folowing people: Mr. Sandesh C. Seth, Chairman & CEO (Age 55)Mr. Steven O'Loughlin BS, Principal Financial & Accounting Officer (Age 33)Dr. Dale L. Ludwig Ph.D., Chief Scientific Officer (Age 57)Dr. Mark S. Berger, Chief Medical Officer (Age 64)Mr. Anil Kapur, Chief Commercial Officer (Age 50) Who are Actinium Pharmaceuticals' major shareholders? Actinium Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Renaissance Technologies LLC (0.60%), Virtu Financial LLC (0.25%) and UBS Group AG (0.11%). Company insiders that own Actinium Pharmaceuticals stock include Ajit Shetty, Dale L Ludwig, Sandesh Seth and Steve O'loughlin. View Institutional Ownership Trends for Actinium Pharmaceuticals. Which institutional investors are buying Actinium Pharmaceuticals stock? ATNM stock was purchased by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Virtu Financial LLC and UBS Group AG. Company insiders that have bought Actinium Pharmaceuticals stock in the last two years include Ajit Shetty, Dale L Ludwig, Sandesh Seth and Steve O'loughlin. View Insider Buying and Selling for Actinium Pharmaceuticals. How do I buy shares of Actinium Pharmaceuticals? Shares of ATNM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is Actinium Pharmaceuticals' stock price today? One share of ATNM stock can currently be purchased for approximately $0.25. How big of a company is Actinium Pharmaceuticals? Actinium Pharmaceuticals has a market capitalization of $41.24 million. Actinium Pharmaceuticals employs 30 workers across the globe.View Additional Information About Actinium Pharmaceuticals. What is Actinium Pharmaceuticals' official website? The official website for Actinium Pharmaceuticals is http://www.actiniumpharmaceuticals.com/. How can I contact Actinium Pharmaceuticals? Actinium Pharmaceuticals' mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The biotechnology company can be reached via phone at +1-646-6773875. MarketBeat Community Rating for Actinium Pharmaceuticals (NYSEAMERICAN ATNM)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 297 (Vote Outperform)Underperform Votes: 175 (Vote Underperform)Total Votes: 472MarketBeat's community ratings are surveys of what our community members think about Actinium Pharmaceuticals and other stocks. Vote "Outperform" if you believe ATNM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATNM will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/21/2020 by MarketBeat.com StaffFeatured Article: What is the Consumer Price Index (CPI)?
